A composition with antiviral effect
By mixing the 65% ethanol extract of Feiyangcao with 95% ethanol extract at a mass ratio of 1:1, it was prepared as an oral preparation, and the problem of poor treatment of respiratory viruses in the prior art was solved, and the respiratory tract combination was achieved The significant therapeutic effect of cytotoxic viruses is improved, providing a safe and efficient natural antiviral option.
Patent Information
- Application Number
- CN202310106647.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-13
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2043-02-13
AI Technical Summary
Currently, there is a lack of effective drugs to treat respiratory virus infection. The existing interferon and nucleotide treatment methods have side effects, are expensive and prone to recurrence, and there are few researches on respiratory viruses.
Develop a composition containing ethanol extracts of different concentrations of phylla, prepared as an oral preparation as a drug for anti-respiratory syncytial virus by mixing 65% ethanol extract with 95% ethanol extract in mass ratio 1:1. Improve the therapeutic effect.
The therapeutic effect on respiratory syncytial virus has been significantly improved, and the treatment index has increased from 4 or 2 when used alone to 160, providing a new safe and effective antiviral treatment option.
Smart Images

Figure CN115919920B_ABST
Abstract
Description
Technical Field
[0001] The present invention specifically relates to a composition with antiviral effect. Background Art
[0002] Viruses are an important pathogen. 60-70% of human infectious diseases are caused by viral infections. About 3.5 million people die from viral infections every year worldwide. In recent years, respiratory viruses such as influenza virus, SARS virus, and syncytial virus have posed a serious threat to human health. At present, there is no specific drug for the treatment of respiratory viral infections, and interferons and nucleotides are mostly used for treatment, which have obvious side effects, are expensive, and are prone to recurrence. Traditional Chinese medicine has shown great potential with its advantages of multiple targets, low toxicity, and easy access. For example, honeysuckle, isatis root, bupleurum, and licorice have all been proven to have antiviral effects. Therefore, it is of great significance to develop natural anti-respiratory virus Chinese herbal medicines.
[0003] Euphorbia hirta L. is an annual herbaceous plant belonging to the genus Euphorbia in the family Euphorbiaceae. It is widely distributed in mountains, roadsides or under forests in tropical and subtropical areas. Because the stems of Euphorbia hirta are rich in white latex, it is called "milk grass, milk grass, and lactation grass" in East China and Guangdong and Guangxi. Euphorbia hirta is a new species added to the Chinese Pharmacopoeia in 2010. It has the effects of clearing away heat and detoxification, promoting dampness and relieving itching, and promoting lactation. It is mainly used to treat lung abscess, breast abscess, furuncle, skin itching and postpartum oligolactosis. The main chemical components of Euphorbia hirta are flavonoids, tannins, triterpenes and diterpenes. Modern pharmacological studies have shown that these compounds have multiple activities such as anti-inflammatory, antioxidant, antibacterial, tumor inhibition and antiviral.
[0004] Song Long et al., Overview of Research on Chemical Composition and Pharmacological Activity of Herba Lycopodii [J], Chinese Herbal Medicine, 2012, 35(6) disclosed that the methanol extract of Herba Lycopodii has antiviral effect, but it is targeted at HIV virus. There is no research on Herba Lycopodii against respiratory viruses. Summary of the invention
[0005] To solve the above problems, the present invention provides a composition with antiviral effect, which comprises extracts of Herba Lysimachiae with different ethanol concentrations, wherein the ethanol concentration is at least 60-70% ethanol and / or 90-100% ethanol.
[0006] Furthermore, the ethanol concentration is 60-70% ethanol and 90-100% ethanol, and the mass ratio of the ethanol extract is: 60-70% ethanol extract: 90-100% ethanol extract = 1-10: 1-10.
[0007] Furthermore, the ethanol concentration is 65% ethanol and 95% ethanol, and the mass ratio of the ethanol extract is: 65% ethanol extract: 95% ethanol extract = 1:1.
[0008] Furthermore, the 95% ethanol extract is obtained by extracting the herb with 95% ethanol, filtering and concentrating the extract, decolorizing it with activated carbon, and freeze-drying it;
[0009] The 65% ethanol extract is obtained by extracting the herb with 65% ethanol, filtering and evaporating the extract to an extract form, and freeze-drying the extract.
[0010] Furthermore, the invention is a preparation prepared by taking 65% ethanol extract and 95% ethanol extract of ophiopogon aviculare as active ingredients and adding pharmaceutically acceptable auxiliary materials.
[0011] Furthermore, the preparation is an oral preparation.
[0012] Furthermore, the oral preparation is a granule, a powder, a paste, a pill or a solution.
[0013] The present invention also provides a method for preparing the above-mentioned composition, which comprises the following steps:
[0014] (1) Take Herba Lysimachiae, add 95% ethanol to extract, filter, concentrate the filtrate, decolorize with activated carbon, and freeze-dry to obtain a 95% ethanol extract of Herba Lysimachiae;
[0015] (2) extracting the herb with 65% ethanol, filtering, evaporating the filtrate to an extract, and freeze-drying to obtain a 65% ethanol extract of the herb;
[0016] (3) Take the 95% ethanol extract of Herba Lycopodiellae in step 1) and the 65% ethanol extract of Herba Lycopodiellae in step 2), mix them in a mass ratio of 1:1, and add excipients or auxiliary ingredients commonly used in medicines to obtain the product.
[0017] Finally, the present invention provides a use of the aforementioned composition in preparing antiviral drugs.
[0018] Furthermore, the drug is an anti-respiratory virus drug; the respiratory virus is respiratory syncytial virus.
[0019] The cell test of the present invention shows that the therapeutic index of the 65% ethanol extract of Herba Lysimachiae or the 95% ethanol extract of Herba Lysimachiae against respiratory viruses is only 4 or 2 when used alone, but when the 95% ethanol extract of Herba Lysimachiae and the 65% ethanol extract of Herba Lysimachiae are configured in a mass ratio of 1:1, the therapeutic index increases exponentially and reaches 160. The present invention combines the ethanol extracts of Herba Lysimachiae at specific concentrations to significantly improve the therapeutic effect of Herba Lysimachiae against respiratory syncytial virus unexpectedly, which provides a new and safe option for the clinical treatment of diseases caused by respiratory viruses.
[0020] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.
[0021] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 UPLC-HRMS base peak ion chromatogram (BPC) of 95% ethanol extract of Herba Lycopodii (Herba Lycopodii) in negative ion mode
[0023] Figure 2 UPLC-HRMS base peak ion chromatogram (BPC) of 95% ethanol extract of Herba Lycopodii (Herba Lycopodii) in positive ion mode
[0024] Figure 3 UPLC-HRMS base peak ion chromatogram (BPC) of 65% ethanol extract of Herba Lycopodii (Herba Lycopodii) in negative ion mode
[0025] Figure 4 UPLC-HRMS base peak ion chromatogram (BPC) of 65% ethanol extract of Herba Lycopodii (Herba Lycopodii) in positive ion mode DETAILED DESCRIPTION
[0026] Example 1. Preparation of the composition of the present invention
[0027] (1) Take 5 g of dried sample of Herba Lysimachiae and place it in a 500 mL beaker, add 150 mL of 95% ethanol (solid-liquid ratio 1:30), reflux extract at 80°C for 1 h, filter at room temperature, add 0.15 g of activated carbon (1000 mL: 1 g) to the aqueous solution after the filtrate is concentrated under reduced pressure, shake at 80°C for 30 min to decolorize, stand for 48 h, take the supernatant and filter, and freeze-dry the filtrate to obtain a 95% ethanol extract of Herba Lysimachiae;
[0028] (2) Take 5 g of dried sample of Herba Lysimachiae and place it in a 500 mL beaker, add 150 mL of 65% ethanol (solid-liquid ratio 1:30), extract in a water bath at 80°C for 1 h, filter and collect the supernatant, rotary evaporate to an extract, and freeze-dry to obtain a 65% ethanol extract of Herba Lysimachiae;
[0029] (3) Take the 95% ethanol extract of Herba Lycopodiellae in step 1) and the 65% ethanol extract of Herba Lycopodiellae in step 2), mix them in a mass ratio of 1:1, and add excipients or auxiliary ingredients commonly used in medicines to obtain the product.
[0030] Example 2. Preparation of the composition of the present invention
[0031] (1) Take 3 g of dried sample of Herba Lysimachiae and place it in a 500 mL beaker, add 90 mL of 95% ethanol (solid-liquid ratio 1:30), reflux extract at 80°C for 1 h, filter at room temperature, add 0.09 g of activated carbon (1000 mL: 1 g) to the aqueous solution after the filtrate is concentrated under reduced pressure, shake at 80°C for 30 min to decolorize, stand for 48 h, take the supernatant and filter, and freeze-dry the filtrate to obtain a 95% ethanol extract of Herba Lysimachiae;
[0032] (2) 3 g of dried sample of Herba Lysimachiae was placed in a 500 mL beaker, 90 mL of 65% ethanol (solid-liquid ratio 1:30) was added, and the mixture was extracted in a water bath at 80°C for 1 h. The supernatant was collected by filtration, rotary evaporated to an extract, and freeze-dried to obtain a 65% ethanol extract of Herba Lysimachiae;
[0033] (3) Take the 95% ethanol extract of Herba Lycopodii in step 1) and the 65% ethanol extract of Herba Lycopodii in step 2), mix them in a mass ratio of 2:1, and add excipients or auxiliary ingredients commonly used in medicines to obtain the product.
[0034] Example 3. Preparation of the composition of the present invention
[0035] (1) Take 6 g of dried sample of Herba Lysimachiae and place it in a 500 mL beaker, add 180 mL of 95% ethanol (solid-liquid ratio 1:30), reflux extract at 80°C for 1 h, place at room temperature for filtration, add 0.18 g of activated carbon (1000 mL: 1 g) to the aqueous solution after the filtrate is concentrated under reduced pressure, shake at 80°C for 30 min to decolorize, stand for 48 h, take the supernatant and filter, and freeze-dry the filtrate to obtain a 95% ethanol extract of Herba Lysimachiae;
[0036] (2) 6 g of dried sample of Herba Lysimachiae was placed in a 500 mL beaker, 180 mL of 65% ethanol (solid-liquid ratio 1:30) was added, and the mixture was extracted in a water bath at 80°C for 1 h. The supernatant was collected by filtration, rotary evaporated to an extract, and freeze-dried to obtain a 65% ethanol extract of Herba Lysimachiae;
[0037] (3) Take the 95% ethanol extract of Herba Lycopodii in step 1) and the 65% ethanol extract of Herba Lycopodii in step 2), mix them in a mass ratio of 1:2, and add excipients or auxiliary ingredients commonly used in medicines to obtain the product.
[0038] Example 4. Preparation of the composition of the present invention
[0039] (1) Take 4 g of dried sample of Herba Lysimachiae and place it in a 500 mL beaker, add 120 mL of 95% ethanol (solid-liquid ratio 1:30), reflux extract at 80°C for 1 h, filter at room temperature, add 0.12 g of activated carbon (1000 mL: 1 g) to the aqueous solution after the filtrate is concentrated under reduced pressure, shake at 80°C for 30 min to decolorize, stand for 48 h, take the supernatant and filter, and freeze-dry the filtrate to obtain a 95% ethanol extract of Herba Lysimachiae;
[0040] (2) 4 g of dried sample of Herba Lysimachiae was placed in a 500 mL beaker, 120 mL of 65% ethanol was added (solid-liquid ratio 1:30), and the mixture was extracted in a water bath at 80°C for 1 h. The supernatant was collected by filtration, rotary evaporated to an extract, and freeze-dried to obtain a 65% ethanol extract of Herba Lysimachiae;
[0041] (3) Take the 95% ethanol extract of Herba Lycopodii in step 1) and the 65% ethanol extract of Herba Lycopodii in step 2), mix them in a mass ratio of 5:1, and add excipients or auxiliary ingredients commonly used in medicines to obtain the product.
[0042] Example 5. Preparation of the composition of the present invention
[0043] (1) Take 7 g of dried sample of Herba Lysimachiae and place it in a 500 mL beaker, add 210 mL of 95% ethanol (solid-liquid ratio 1:30), reflux extract at 80°C for 1 h, filter at room temperature, add 0.21 g of activated carbon (1000 mL: 1 g) to the aqueous solution after the filtrate is concentrated under reduced pressure, shake at 80°C for 30 min to decolorize, stand for 48 h, take the supernatant and filter, and freeze-dry the filtrate to obtain a 95% ethanol extract of Herba Lysimachiae;
[0044] (2) 7 g of dried sample of Herba Lysimachiae was placed in a 500 mL beaker, 210 mL of 65% ethanol was added (solid-liquid ratio 1:30), and the mixture was extracted in a water bath at 80°C for 1 h. The supernatant was collected by filtration, rotary evaporated to an extract, and freeze-dried to obtain a 65% ethanol extract of Herba Lysimachiae;
[0045] (3) Take the 95% ethanol extract of Herba Lycopodii in step 1) and the 65% ethanol extract of Herba Lycopodii in step 2), mix them in a mass ratio of 1:5, and add excipients or auxiliary ingredients commonly used in medicines to obtain the product.
[0046] The beneficial effects of the present invention are described below through test examples.
[0047] Experimental Example 1 Study on the in vitro anti-respiratory virus activity of the ethanol extract of the present invention
[0048] 1. Materials and Methods
[0049] 1.1 Materials
[0050] Plant materials: Feiyangcao was collected from Miyi, Sichuan Province, and identified by Associate Professor Bai Jie from the School of Life Sciences of Sichuan University. After washing to remove dust, drying at 60℃, crushing and passing through a 200-mesh sieve for later use.
[0051] Viruses: Influenza A(H1N1) virus (PR8 strain, FM1 strain) (H1N1), influenza A(H3N2) virus (brisbane / 10 / 2009) (H3N2), influenza B virus (Jiangxi Xiushui / 32 / 2009) (FluB), parainfluenza virus (PIV), respiratory syncytial virus (RSV), adenovirus (type 3) (ADVⅢ), human coronavirus 229E (HCoV-229E), and human coronavirus OC43 (HCoV-OC43) were purchased from ATCC and stored at −80°C in the laboratory of China Medical University.
[0052] Cells: Human lung cancer cells (A549), canine kidney cells (MDCK), and colon cancer cells (HCT-8) were purchased from Beijing Beina Chuanglian Biotechnology Research Institute and stored in liquid nitrogen for future use.
[0053] Reagents: acetonitrile, methanol, and formic acid were of chromatographic grade; ethanol was of analytical grade (Merck); purified water (Guangzhou Watsons Food and Beverage Co., Ltd.); DMEM culture medium, penicillin-streptomycin double antibody, trypsin-EDTA (ThermoFisher, USA); fetal bovine serum (Cellgro, USA); PBS (Corning, USA).
[0054] 1.2 Experimental methods
[0055] 1.2.1 Extraction of active ingredients from Psoralea corylifolia and preparation of test drugs
[0056] Weigh 5g of dried sample of spatholobi and place it in a 500mL beaker, add 150mL of 95% ethanol (solid-liquid ratio 1:30), reflux extract at 80℃ for 1h, filter at room temperature, add 0.15g of activated carbon (1000mL:1g) to the aqueous solution after the filtrate is concentrated under reduced pressure, shake at 80℃ for 30min to decolorize, let stand for 48h, filter the supernatant, and freeze-dry the filtrate. Weigh another 5g of dried sample of spatholobi and place it in a 500mL beaker, add 150mL of 65% ethanol (solid-liquid ratio 1:30), extract at 80℃ water bath for 1h, filter and collect the supernatant, rotary evaporate to extract, and freeze-dry for later use.
[0057] Weigh 1 g of 95% ethanol extract of Herba Lycopodiellae and mark it as "Drug 1#"; weigh 1 g of 65% ethanol extract of Herba Lycopodiellae and mark it as "Drug 2#"; weigh 1 g of 95% ethanol extract of Herba Lycopodiellae and 65% ethanol extract of Herba Lycopodiellae in a mass ratio of 1:1 and mark it as "Drug 3#".
[0058] 1.2.2 Toxicity test of the test drugs on A549, MDCK and HCT-8 cells
[0059] The test drugs 1#, 2#, and 3# were prepared into 10 mg / mL stock solutions (sterile filtration) with purified water, and then the stock solutions were diluted 2-fold with culture medium (DMEM culture medium + 1% penicillin-streptomycin double antibody + 10% fetal bovine serum) to prepare 8 different concentrations, and 100 μL / well was added to 96-well culture plates that had grown into monolayers of A549 cells, MDCK cells, and HCT-8 cells. Four replicate wells were made for each drug concentration, and normal cells were set as controls. The cells were placed in a 37°C, 5% CO2 incubator for continuous culture (Shanghai Lishen Scientific Instrument Co., Ltd.) for 72 hours, and the cell pathological changes were observed under an inverted microscope every day to determine the lowest dilution concentration (maximum non-toxic concentration TC0) at which the cells did not show obvious pathological changes, and the 50% cytotoxic concentration (TC0) of the test drug was calculated according to the Reed-Muench method. 50 The cytopathic effect was judged according to the 6-grade standard: -: normal cell growth, no lesions; ±: less than 10% of the whole monolayer of cells; +: less than 25% of the whole monolayer of cells; ++: less than 50% of the whole monolayer of cells; +++: less than 75% of the whole monolayer of cells; ++++: more than 75% of the whole monolayer of cells.
[0060] 1.2.3 In vitro inhibitory effects of the test drugs on HCoV-229E and HCoV-OC43 viruses
[0061] A549 cells and HCT-8 cells were cultured in 96-well culture plates. After the cells grew to a monolayer, the culture medium was discarded. The cell surface was washed three times with cell maintenance medium (DMEM culture medium) and then 100 TCID 50(Half infection dose) HCoV-229E virus and HCoV-OC43 virus infect the corresponding A549 and HCT-8 monolayer cells respectively, place them in a 37°C, 5% CO2 incubator for adsorption for 2 hours, then discard the virus solution, add 100 μL / well of each drug solution with 5 dilutions below the maximum non-toxic concentration in turn, and repeat 4 wells for each drug concentration. At the same time, set up a normal cell control group and a virus control group. Place them in a 37°C, 5% CO2 incubator and culture continuously for 96 hours. Observe the cell lesions under an inverted microscope every day. Record the test results when the cell lesions in the virus control group are ++~++++. Calculate the 50% inhibitory concentration (IC) according to Reed-Muench. 50 ) and therapeutic index (TI), TI = TC 50 / IC 50 .
[0062] 1.2.4 In vitro inhibitory effects of the test drugs on influenza A (H1N1) virus (PR8 strain, FM1 strain), influenza A (H3N2) virus (brisbane / 10 / 2009), influenza B virus (Jiangxi Xiushui / 32 / 2009), parainfluenza virus, respiratory syncytial virus, and adenovirus (type 3).
[0063] MDCK cells were cultured in 96-well culture plates. After the cells grew to a monolayer, the culture medium was discarded. The cell surface was washed three times with cell maintenance medium and then 100 TCID 50 Monolayer cells were infected with influenza A (H1N1) virus (PR8 strain, FM1 strain), influenza A (H3N2) virus (brisbane / 10 / 2009), influenza B virus (Jiangxi Xiushui / 32 / 2009), parainfluenza virus, respiratory syncytial virus, and adenovirus (type 3). After adsorption for 2 hours in a 37°C, 5% CO2 incubator, the virus solution was discarded, and 100 μL / well of each drug solution with 5 dilutions below the maximum non-toxic concentration was added in sequence. Each drug concentration was repeated in 4 wells, and a normal cell control group and a virus control group were set up. The cells were cultured continuously in a 37°C, 5% CO2 incubator for 72h-96h, and the cell lesions were observed under an inverted microscope every day. The test results were recorded when the cell lesions in the virus control group were ++~++++. The 50% inhibitory concentration (IC) was calculated according to Reed-Muench. 50 ) and therapeutic index (TI), TI = TC 50 / IC 50 .
[0064] 1.2.5 UPLC-Q-TOF / MS analysis of antiviral active ingredients
[0065] Preparation of test solution: Accurately weigh 1 mg each of 95% ethanol extract of Herba Lycopodii and 65% ethanol extract of Herba Lycopodii, place them in a 10 mL beaker, dissolve them in 8 mL of 80% chromatographic methanol, and filter them with a 0.22 μm microporous filter membrane to obtain sample solutions.
[0066] 65% ethanol extract Chromatographic conditions: Column, Waters T3 (2.1×100mm, 1.6μm); column temperature, 30℃; injection volume, 2μL; detection wavelength, 254nm; flow rate, 0.3mL / min; mobile phase ratio and flow rate, phase A: acetonitrile, phase B: 0.1% formic acid aqueous solution, gradient see Table 1.
[0067] Table 1 Mobile phase gradient
[0068] Time(min) A% B% 0~5 0~8 100~92 5~20 8~25 92~75 20~25 25~50 75~50 25~30 50~70 50~30 30~33 70~90 30~10 34~35 90 10
[0069] Chromatographic conditions for 95% ethanol extract: chromatographic column, Agilent ZORBAX SB-C18 Rapid Resolution HD (2.1x100mm 1.8micron); column temperature, 40°C; injection volume, 6μL; detection wavelength, 254nm; flow rate, 0.4mL / min; mobile phase ratio and flow rate, phase A 0.1% formic acid aqueous solution, phase B acetonitrile, gradient see Table 2.
[0070] Table 2 Mobile phase gradient
[0071] Time(min) A% B% 0~1 98 2 1~10 98 2 10~12 5 95 12~12.1 5 95 12.1~15 98 2
[0072] Mass spectrometry conditions: mass spectrometry detection mode, ESI-Negative / Positive ion mode; mass spectrometry parameters are shown in Table 3.
[0073] Table 3 MS parameters (Agilent 6545Q-TOF LC-MS)
[0074]
[0075]
[0076] UPLC-Q-TOF / MS analysis: 65% ethanol extract and 95% ethanol extract of Herba Lycopodii were analyzed by ultra-high performance liquid chromatography-high resolution mass spectrometry (UPLC-Q-TOF / MS). Agilent 1290UPLC ultra-high performance liquid chromatograph, Agilent Q-TOF 6545LC / MS high-resolution tandem mass spectrometer, and Agilent 5977A GC / MSD gas chromatography-mass spectrometer were used (Agilent Technologies, Inc.).
[0077] The data acquisition software is MassHunter Workstation Software LC / MS Data Acquisitionfor 6200series TOF / 6500series Q-TOF (version B.06.01), and the data processing software is MassHunterWorkstation Software Qualitative Analysis (version B.07.00). During identification, the mass spectrometry data is matched with the MassHunter PCDL Manager (version B.07.00) database, and the compounds are preliminarily screened according to the score information of each chromatographic peak, and further confirmed according to the primary and secondary information of each chromatographic peak.
[0078] 2. Experimental results
[0079] 2.1 In vitro antiviral activity of the tested drugs
[0080] 2.1.1 Toxic effects of the test drugs on A549, MDCK, and HCT-8 cells
[0081] The maximum non-toxic concentration (TC0) of the tested drugs 1#, 2#, and 3# for A549 cells was 0.08 mg / mL, and the half toxic concentration (TC 50 ) averaged 0.11 mg / mL; the average TC0 for HCT-8 cells was 0.08 mg / mL, TC 50 The average value is 0.11 mg / mL; the average value of TC0 for MDCK cells is 0.039 mg / mL, and the average value of TC 50 The average value was 0.056 mg / mL (see Table 4).
[0082] Table 4 Toxicity of the tested drugs to A549, HCT-8 and MDCK cells cultured in vitro
[0083]
[0084]
[0085] Note: Cytopathic score: - means no CPE, “+” = 1, “++” = 2, “+++” = 3, “++++” = 4; all data of 4 replicate wells were recorded.
[0086] 2.1.2 Inhibitory effect of the test drugs on HCoV-229E and HCoV-OC43 viruses in A549 and HCT-8 cells cultured in vitro
[0087] The tested drugs had no inhibitory effect on the pathological changes of A549 cells cultured in vitro induced by HCoV-229E virus at different concentrations, but had different degrees of inhibitory effects on the pathological changes of HCT-8 cells cultured in vitro induced by HCoV-OC43 virus. The upper half inhibitory concentration (IC 50 ) were all 0.028 mg / mL, and the therapeutic index (TI) was 4 (see Table 5).
[0088] Table 5 In vitro inhibitory effects of the tested drugs on HCoV-229E and HCoV-OC43 viruses
[0089]
[0090]
[0091] Note: Cytopathic score: “+” = 1, “++” = 2, “+++” = 3, “++++” = 4; all data of 4 replicate wells were recorded.
[0092] 2.1.3 The inhibitory effect of the test drugs on influenza A (H1N1) virus (PR8 strain, FM1 strain), influenza A (H3N2) virus (brisbane / 10 / 2009), influenza B virus (Jiangxi Xiushui / 32 / 2009), parainfluenza virus, respiratory syncytial virus, and adenovirus (type 3) in MDCK cells cultured in vitro.
[0093] The tested drugs had no significant inhibitory effect on MDCK cell pathology induced by influenza A(H1N1) virus (PR8 strain, FM1 strain), influenza A(H3N2) virus (brisbane / 10 / 2009), influenza B virus (Jiangxi Xiushui / 32 / 2009), parainfluenza virus, and adenovirus (type 3) at different concentrations, but had different degrees of inhibitory effect on MDCK cell pathology induced by respiratory syncytial virus. The half inhibitory concentration (IC50) of drugs 1#, 2#, and 3# on MDCK cells was 50 ) were 0.014 mg / mL, 0.028 mg / mL, and 0.0035 mg / mL, respectively, and the therapeutic index (TI) was 4, 2, and 160, respectively (Table 6). Drug 3# had a strong inhibitory effect on syncytial virus, and the antiviral activity increased in a concentration-dependent manner.
[0094]
[0095]
[0096] 2.2 UPLC-Q-TOF / MS analysis of active ingredients
[0097] UPLC-Q-TOF / MS was used to analyze the 95% ethanol extract and 65% ethanol extract of Herba Lysimachiae, and the total ion chromatogram ( Figure 1-4 ). According to the multi-level mass spectrometry information of the samples and the natural product high-resolution mass spectrometry database, 14 compounds were identified from the 95% ethanol extract of Herba Lycopodii, including 7 flavonoids and 7 triterpenoids (Table 7); 37 compounds were identified from the 65% ethanol extract of Herba Lycopodii, including 23 polyphenols, 5 amino acids, 3 sugars, 2 alkaloids, 1 organic acid, 1 caffeoylquinic acid, and 1 phenolic acid compound. Among the polyphenols, most were flavonoids (Table 8).
[0098] Table 7 Identification results of main components of 95% ethanol extract of Herba Lysimachiae
[0099]
[0100] Table 8 Identification results of main components of 65% ethanol extract of Herba Lysimachiae
[0101]
[0102]
[0103] 3. Discussion
[0104] Respiratory virus is a type of RNA virus that is highly contagious. Through in vitro antiviral experiments, the present invention found that the 65% ethanol extract and 95% ethanol extract of Herba Lycopodii have inhibitory effects on human coronavirus OC43 and respiratory syncytial virus. Among them, the preparation of the 65% ethanol extract of Herba Lycopodii and the 95% ethanol extract of Herba Lycopodii in a mass ratio of 1:1 showed a more obvious inhibitory effect on respiratory syncytial virus than the use of the two alcohol extracts alone. After the virus infected MDCK cells, the addition of the mixed ethanol extract of Herba Lycopodii inhibited the CPE caused by the virus, and with the increase in concentration, the degree of cell pathology caused by the virus gradually weakened. Its half inhibitory concentration (IC 50 ) was 0.0035 mg / mL, indicating that Flying Grass had a strong inhibitory effect on syncytial virus in vitro, and the therapeutic index (TI) reached 160, indicating that it had high effectiveness.
[0105] Through qualitative analysis of the active ingredients in the alcohol extract of scutellaria baicalensis, the main active ingredients were initially identified as flavonoids such as baicalin, quercetin, and myricetin. Flavonoids are widely present in nature and have multiple pharmacological effects such as antiviral, anti-inflammatory, anticancer, and antibacterial. Yan Chunmin concluded through flow cytometry that quercetin and isoquercetin can inhibit the infection of HSV-1 and HSV-2; He Yujiao et al. found that myricetin inhibited the replication of hepatitis C virus by inhibiting the expression of microRNA-122; Liu Hejuan showed that baicalin can inhibit swine D-coronavirus infection based on network pharmacology analysis; Meng Xin believed that baicalin can reduce lung inflammation in BALB / c mice caused by RSV infection. The present invention found through observation of CPE that the anti-respiratory syncytial virus effect of the mixed preparation of two ethanol extracts of scutellaria baicalensis was better than that of each ethanol extract alone, indicating that the antiviral activity of scutellaria baicalensis may be the result of the synergistic effect of multiple components. At the same time, based on the results of the alcohol extract's inhibition of virus penetration, it is speculated that the flying grass may inhibit syncytial virus by preventing the virus from adsorbing target cells or affecting the virus biosynthesis pathway.
[0106] The rapid mutation of viruses poses a huge challenge to drug screening and development. Traditional Chinese medicine has shown great potential with its advantages of multiple targets, low toxicity and easy access. Compared with Western medicine, traditional Chinese medicine has multiple active ingredients and kills viruses through multiple pathways. It can play its antiviral role by enhancing the body's immune ability, inhibiting viral invasion, interfering with viral DNA and RNA replication, and traditional Chinese medicine rarely shows drug resistance and toxic side effects in the process of virus prevention and treatment. The ethanol extract of lycopodiella is a natural compound with low toxicity and high anti-syncytial virus effect. Therefore, lycopodiella has the potential to be developed into a new natural anti-respiratory virus drug.
Claims
1. A composition having an anti-respiratory syncytial virus effect, characterized in that: It is made of extracts of different concentrations of ethanol from the herb; the ethanol concentrations are 65% ethanol and 95% ethanol, and the mass ratio of the ethanol extracts is: 65% ethanol extract: 95% ethanol extract = 1:1; The 95% ethanol extract is obtained by extracting the herb with 95% ethanol, filtering and concentrating the extract, decolorizing it with activated carbon, and freeze-drying it; The 65% ethanol extract is obtained by extracting the herb with 65% ethanol, filtering the extract, evaporating it to an extract form, and freeze-drying it.
2. The composition according to claim 1, characterized in that: The invention is a preparation prepared by taking 65% ethanol extract and 95% ethanol extract of smilax china as active ingredients and adding pharmaceutically acceptable auxiliary materials.
3. The composition according to claim 2, characterized in that: The preparation is an oral preparation or an external preparation.
4. The composition according to claim 3, characterized in that: The oral preparation is a granule, powder, paste, pill or solution; the external preparation is a spray or aerosol.
5. The composition according to claim 3, characterized in that: The external preparation is a solution.
6. A method for preparing the composition according to any one of claims 1 to 5, characterized in that: It includes the following steps: (1) Take Herba Lycopodii, add 95% ethanol to extract, filter, concentrate the filtrate, decolorize with activated carbon, and freeze-dry to obtain Herba Lycopodii 95% ethanol extract; (2) Take the herb of lycopodiella ciliata, add 65% ethanol to extract, filter, evaporate the filtrate to an extract, and freeze-dry to obtain a 65% ethanol extract of the herb of lycopodiella ciliata; (3) Take the 95% ethanol extract of Herba Lycopodii in step 1) and the 65% ethanol extract of Herba Lycopodii in step 2), mix them in a mass ratio of 1:1, and add excipients or auxiliary ingredients commonly used in medicines to prepare the product.
7. Use of the composition according to any one of claims 1 to 5 in the preparation of an antiviral drug; characterized in that: The drug is an anti-respiratory virus drug; the respiratory virus is respiratory syncytial virus.
